Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer

Yan Zheng1, Chao Wu1, Jimeng Yang1, Yue Zhao2, Huliang Jia1, Min Xue1, Da Xu1, Peng Yang3, Deliang Fu3, Chaoqun Wang1, Beiyuan Hu1, Ze Zhang1, Tianen Li1, Shican Yan1, Xuan Wang1, Peter J. Nelson4, Christiane Bruns2, Lunxiu Qin1 and Qiongzhu Dong1

Enolase 2 (ENO2) is a key glycolytic enzyme in the metabolic process of glycolysis, but its potential function in pancreatic ductal adenocarcinoma (PDAC) is unclear. In this study, we observed a significant overexpression of ENO2 in PDAC tissues, and its expression was correlated with metastasis and poor prognosis in PDAC patients. K394 was identified as a major acetylation site in ENO2 that regulates its enzymatic activity, cell metabolism and PDAC progression. Knockdown of ENO2 suppressed tumor growth and liver metastasis in PDAC. Re-expression of wild-type (WT) ENO2, but not the K394 acetylation mimetic mutant, could reverse the decreased tumor malignancy. We further characterized histone deacetylase 3 (HDAC3) and P300/CBP-associated factor (PCAF) as the potential deacetylase and acetyltransferase for ENO2, respectively. HDAC3-mediated deacetylation was shown to lead to ENO2 activation and enhancement of glycolysis. Importantly, insulin-like growth factor-1 (IGF-1) was found to decrease K394 acetylation and stimulate ENO2 activity in a dose- and time-dependent manner. The PI3K/AKT/mTOR pathway facilitated the phosphorylation of HDAC3 on S424, which promoted K394 deacetylation and activation of ENO2. Linsitinib, an oral small-molecule inhibitor of IGF-1R, could inhibit IGF-1-induced ENO2 deacetylation by HDAC3 and the PI3K/AKT/mTOR pathway. Furthermore, linsitinib showed a different effect on the growth and metastasis of PDAC depending on the overexpression of WT versus K394-mutant ENO2. Our results reveal a novel mechanism by which acetylation negatively regulates ENO2 activity in the metastasis of PDAC by modulating glycolysis. Blockade of IGF-1-induced ENO2 deacetylation represents a promising strategy to prevent the development of PDAC.

Signal Transduction and Targeted Therapy (2020)5:53 ; https://doi.org/10.1038/s41392-020-0146-6

INTRODUCTION
Pancreatic cancer is one of the most rapidly lethal cancers. Recent data show that the 5-year survival of patients with pancreatic carcinoma remains as low as 5–15% worldwide. To date, pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic carcinoma, accounting for 85% of all pancreatic neoplasms and presenting with a very poor prognosis. With the development of new therapeutic strategies, the mortality of PDAC is still high. One of the major hallmarks of PDAC is metastasis. Over 50% of patients are diagnosed with local lymph node or distant organ metastasis, and they lose the opportunity for surgical treatment. Therefore, deciphering the mechanisms underlying PDAC metastasis may allow early intervention and improve the prognosis of this disease.

Recent studies have reported that alterations in cell metabolism contribute to malignant transformation and cancer progression. The dysregulation of cellular metabolism is now recognized as a core feature of cancer cells. In general, cancer cells exhibit a unique aerobic glycolysis phenotype for more metabolic substrate acquisition during tumorigenesis and metastasis (Warburg effect). Previous work from our group identified a set of altered metabolic genes and metabolites associated with liver cancer progression. PDAC cells are well adapted to grow in the context of severe metabolic stress, as the hypovascular, fibrotic tumor microenvironment results in extreme hypoxia and limited nutrient availability. Extensively reprogrammed metabolism is seen in PDAC, which helps foster the different energetic and biosynthetic demands seen. A recent study elucidated that glucose metabolism is involved in pancreatic tumors and that inhibition of glycogen synthase kinase 3 beta retards cancer progression in mice. Alterations in metabolic protein expression and associated post-translational modification (PTM) effects may underlie the necessary adaptive changes seen in cancer cell metabolism.

Lysine acetylation (Kac) is an important reversible and dynamic protein PTM. A recent study reported that acetylation of the glycolytic enzyme phosphoglycerate kinase 1 could enhance the malignancy of liver cancer cells. Similarly, acetylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 was found to lead to cytoplasmic accumulation of this enzyme, which helped cells avoid apoptosis by enhancing glycolysis. Notably, this general phenomenon is not only associated with glucose metabolism. The majority of intermediate metabolic enzymes in lipid and glutamine metabolism have also been found to undergo
Acetylation. Thus, the acetylation status can affect enzyme activity and cellular metabolism. The dysregulation of lysine acetylation may contribute to diverse pathological conditions, such as cancers.

In the glycolytic penultimate step, enolase 2 (ENO2), also called neuro-specific enolase (NSE), is responsible for the conversion of 2-phosphoglycerate (2-PGA) to phosphoenolpyruvate (PEP). ENO2 is a well-established tumor biomarker for cancers such as neuroendocrine tumors, prostate cancer, small-cell lung cancer, and metastatic neuroblastoma and the microvascular invasion status of liver cancer. In our previous gene expression profiling study, we found that ENO2 was one of the leading genes associated with the metastasis of hepatocellular carcinoma (HCC). To our knowledge, the relationship between ENO2 and PDAC has not been studied. Moreover, previous studies reported that ENO2 might be acetylated. Thus, a better understanding of the potential role of ENO2...
Fig. 1 High ENO2 expression is closely associated with poor outcomes of patients with PDAC. a ENO2 mRNA levels in pancreatic tumor tissues and corresponding normal tissues in two independent GEO datasets (GSE28735, n = 45; GSE15471, n = 36). b Representative IHC staining results of ENO2: left panel: normal tissue; middle panel: low ENO2 expression; right panel: high ENO2 expression; scale bar = 400 μm or 100 μm. c High or low expression of ENO2 in tumor (n = 271) or adjacent normal tissues (n = 161) in the TMA cohort. d Existence or absence of lymph node metastasis in the low or high ENO2 expression group in the TMA cohort (ENO2 high, n = 136; ENO2 low, n = 135). e, f The protein levels of ENO2 in PDAC samples. Twelve pairs of tumor (T) and adjacent normal tissues (N) (n = 12 per group) and eight tumor samples with or without liver metastasis (f) were analyzed by western blot with ENO2 antibody. Relative ENO2 protein levels were normalized against β-actin. MFPs, metastasis-free patients (n = 4); LMPs, liver metastasis patients (n = 4). g Overall survival rates in PDAC patients with low (n = 135) or high (n = 136) ENO2 expression assessed by Kaplan–Meier analysis. h Probability of tumor recurrence rates in PDAC patients with low (n = 135) or high (n = 136) ENO2 expression assessed by Kaplan–Meier analysis. Error bars represent the mean ± SD, and the dots represent the value of each experiment; ***P < 0.001. A paired t test was employed in (a) and (e), an unpaired t test was employed in (f), Fisher exact test was employed in (c), the chi-square test was employed in (d), and the log-rank test was employed in (g) and (h).

RESULTS
ENO2 correlates with metastasis and prognosis of PDAC
To investigate the possible role of ENO2 in pancreatic cancer progression, we first analyzed ENO2 mRNA levels based on two Gene Expression Omnibus (GEO) datasets (GSE28735 and GSE15471). Overall, ENO2 mRNA was found to be significantly increased in pancreatic cancer tissues compared with normal tissues (Fig. 1a, P < 0.001). To confirm these findings from published microarray datasets, immunohistochemistry (IHC) staining was used to assess the protein levels of ENO2 in 271 human PDAC tumors and 161 normal tissues from our hospital. Similar to what was found in public data, the protein level of ENO2 was also significantly increased in PDAC tissues compared with normal tissues in the cohort from our hospital (Fig. 1b, c). Interestingly, a significant difference in ENO2 expression was also observed between PDAC with lymphatic metastasis and metastasis-free tumors (Fig. 1d, P < 0.001). To further confirm the mRNA and IHC findings, we used immunoblotting to assess the expression levels of ENO2 in PDAC tissues from 12 patients. ENO2 protein levels were confirmed to be significantly higher in the PDAC tissues than in their matched normal tissues (Fig. 1e). Furthermore, in comparison with that in nonmetastatic PDAC tissues, the protein level of ENO2 was found to be increased in PDAC tissues with liver metastasis (Fig. 1f), suggesting that ENO2 may be involved in PDAC progression.

In addition, higher ENO2 expression levels also correlated with poor overall survival rates (OS) and an increased incidence of recurrence compared with low ENO2 expression levels (Fig. 1g, h). To better characterize the potential association between ENO2 expression and the prognosis of PDAC patients, the general correlation between ENO2 IHC staining in PDAC samples and patient clinicopathological features and prognosis after surgery was evaluated. ENO2 levels in tumor tissues were found to be significantly associated with tumor differentiation (P = 0.004) and lymph node metastasis (P < 0.001, Supplementary Table S1). Using univariate analysis, ENO2 expression, sex, CA19-9 level and tumor differentiation were shown to be significantly associated with OS and the probability of recurrence rate (PRR). In multivariate analyses, the prognostic value of ENO2 for OS and the PRR was independent of all other clinical variables tested (Supplementary Table S2). Collectively, these results suggest that high ENO2 expression is associated with poorer prognosis and worse malignancy than low ENO2 expression in PDAC.

ENO2 is acetylated at K394 in PDAC
Previous proteomic studies have shown that ENO2 is acetylated on multiple lysine residues.17,18 To confirm this acetylation, Flag-tagged ENO2 was ectopically expressed in HEK293T (Fig. 2a, left) and pancreatic cancer cells (Fig. 2a, right), and the acetylation level was tested using a pan-anti-acetylated lysine antibody. The results demonstrated that ectopically expressed ENO2 was indeed acetylated and that its acetylation was significantly increased after treatment with trichostatin A (TSA), an inhibitor of HDACs, but not after treatment with nicotinamide (NAM), an inhibitor of the SIRT family deacetylases. Furthermore, the acetylation level of ENO2 was increased by TSA treatment in a time- (Fig. 2b) and dose-dependent (Fig. 2c) manner, suggesting that ENO2 is acetylated in PDAC.

After confirming that ENO2 was acetylated, we then sought to identify which residue in ENO2 represented the functional acetylation regulatory site. Among the six potential sites identified, two of the lysine residues (K343 and K394) are located in the active center of ENO2, while the other four (K193, K197, K202, and K228) have been previously described.17,18 To determine which lysine residue(s) plays a major role in the regulation of ENO2, each of the acetylated lysine residues in ENO2 was mutated to arginine (R), and the acetylation level and enzyme activity were evaluated individually. Among the sites identified, substitution at K394, but not at the other five lysine residues, substantially reduced ENO2 acetylation (Fig. 2d) and enzyme activity (Fig. 2e), indicating that K394 plays an important role in controlling ENO2 activity. In addition, K394 was found to be evolutionarily conserved across several different species (Fig. 2f). To further characterize the K394 acetylation site, an antibody (AcK394-ENO2) was generated that specifically recognizes ENO2 when it is acetylated at the K394 site (Supplementary Fig. S1a). Dot blot assays showed that the AcK394 antibody preferentially detected the acetylated peptide but not the unmodified peptide, demonstrating the specificity of this antibody (Fig. 2g). K394 acetylation was further verified by immunoprecipitation (IP) of endogenous ENO2 in HEK293T and pancreatic cancer cells (Fig. 2h). Importantly, the K394 acetylation level of ENO2 could be increased by treatment with TSA. However, both the K394R and K394Q mutants exhibited a negligible change in acetylation levels upon TSA treatment (Fig. 2i). Because ENO2 is an important glycolytic enzyme contributing to cancer cell energetics, we hypothesized that K394 acetylation may modulate ENO2 enzymatic activity. As expected, both the K394R and K394Q mutants exhibited much lower activity than WT ENO2 (Fig. 2j), reaffirming that K394 is a major acetylation site in ENO2.

ENO2 K394 deacetylation is crucial for PDAC glycolysis and metastasis
To address the functional significance of ENO2 regulation by K394 acetylation, we generated stable PDAC cells in which endogenous

...
ENO2 was depleted, and WT or K394-mutant ENO2 was reintroduced (Supplementary Fig. S1b, c). Because ENO2 is a major metabolic enzyme in the glycolysis pathway, we used extracellular acidification measurements to determine the potential changes in metabolism after ENO2 K394 acetylation. Depletion of endogenous ENO2 decreased the extracellular acidification rate (ECAR) of cells to suppress glycolysis, which was effectively restored by re-expression of WT ENO2 but not with...

---

**Fig. 2** Acetylation of ENO2 at K394 decreases its enzymatic activity. a Flag-ENO2 was ectopically expressed in HEK293T and Colo357 cells, followed by treatment with NAM (nicotinamide, 10 mM for 6 h), TSA (trichostatin, 5 μM for 12 h), or both (N + T: nicotinamide, 10 mM for 6 h and trichostatin, 5 μM for 12 h). Acetylation levels of immunopurified Flag-ENO2 were examined by western blot analysis with a pan-acetylated lysine antibody (AcK). Relative ENO2 acetylation levels were normalized by Flag. b, c ENO2 acetylation levels were increased by TSA treatment in a time- (b) and dose- (c) dependent manner. HEK293T and Colo357 cells overexpressing Flag-ENO2 were treated with 5 μM TSA for 0, 4, 8, or 12 h or with 0 μM, 2.5 μM, 5 μM or 10 μM TSA for 8 h. ENO2 acetylation was determined by western blot with AcK.

d, e Mapping the major regulatory sites of acetylation in ENO2. Flag-tagged WT ENO2 and the K193R, K197R, K202R, K228R, K343R, and K394R mutants were each overexpressed in HEK293T cells. Flag-ENO2 was immunoprecipitated, and its acetylation was examined with AcK, normalized against Flag. f K394 in ENO2 is evolutionarily conserved. The sequences around ENO2 K394 from different species are shown.

**g** Characterization of the anti-acetyl-ENO2 (AcK394) antibody. Different amounts of acetyl-K394 peptide or unmodified peptide were spotted on nitrocellulose membranes, and the specificity of the antibody against the acetylated K394 residue was determined by dot blot assay. h Endogenous ENO2 protein was immunoprecipitated with anti-ENO2 antibody from HEK293T and Colo357 cells treated with NAM and TSA as indicated (NAM, 10 mM for 6 h; TSA, 5 μM for 12 h; or both NAM and TSA treatment). Acetylation levels of K394 were analyzed with an antibody specifically recognizing the acetylated ENO2 K394 residue (AcK394). Relative K394 acetylation levels were normalized against ENO2 protein. i, j K394 is the major acetylation residue of ENO2. Flag-tagged wild-type ENO2 and the K394Q and K394R mutants were each overexpressed in HEK293T cells, followed by treatments with or without 5 μM TSA for 8 h. The acetylation levels (i) and enzyme activity (j) of ENO2 were analyzed. The group with WT ENO2 served as the control group; n = 3 per group. Error bars represent the mean ± SD, and the dots represent the value of each experiment; **P < 0.01, ***P < 0.001, ns: no significance. Statistical significance was determined by unpaired t test.
the K394 mutants (Fig. 3a and Supplementary Fig. S2a, b). Similar results were observed in tests of lactate production that were performed with the resulting cell lines (Fig. 3b). These findings strongly suggested that ENO2 K394 acetylation represented an essential step in glycolytic metabolism in cancer cells.

Cancer cells depend on enhanced glycolysis to maintain their rapid growth. We hypothesized that K394 acetylation of ENO2 is associated with tumor cell progression. As expected, knockdown of ENO2 resulted in significant suppression of colony formation and invasion. However, the re-expression of WT ENO2, but not of
Fig. 3. ENO2 K394 acetylation represses glycolysis and invasion of PDAC cells in vitro and in vivo. a WT ENO2 and its K394R and K394Q mutants were reintroduced into ENO2 knockdown Colo357 cells. The extracellular acidification rate (ECAR) of the indicated cells was detected by using a Seahorse XF96 Extracellular Flux Analyzer, and the maximum glycolytic rates were summarized, n = 9 per group. b Lactate secretion in the culture medium of the indicated cells for 12 h; n = 4 per group. c, d Colony assays (c) and transwell assays (d) were performed with the indicated Colo357 cells; n = 4 per group (scale bar = 100 μm). e, f Colo357 cells with ENO2 knockdown and Colo357 cells with ENO2 knockdown plus reintroduced wild-type ENO2 or K394Q mutants were implanted into the flank of nude mice (n = 5 per group). The tumor volumes (e, left), tumor weight (e, right) and tumor growth curves (f) of subcutaneous implantation models of PDAC at day 32 are shown. g, h The effect of ENO2 K394 acetylation on metastasis of PDAC in metastatic mouse models (n = 5 per group). Livers were harvested after mice died, and metastatic nodules were counted by H&E staining (See Supplementary Fig. S2e). The total numbers of liver metastatic PDAC samples. Twelve pairs of tumor (T) and adjacent normal tissues (N) (4), LMPs, liver metastasis patients (4). p < 0.01, **p < 0.001, ns: no significance. An unpaired t test was employed in (a–d, j), one-way ANOVA followed by Bonferroni’s post hoc test was employed in (e) and (g), two-way ANOVA followed by Bonferroni’s post hoc test was employed in (f), the log-rank test was employed in (h), and a paired t test was employed in (i).

The K394-mutant, reversed the growth retardation phenotype of Colo357 cells; importantly, WT ENO2, but not the K394-mutant, was found to decrease tumor growth and tumor volume; however, the tumor growth inhibition was reversed by WT ENO2 but not by the K394-mutant (Fig. 3e, f). To further characterize the effects of ENO2 K394 acetylation on tumor metastasis, we developed in vivo metastatic mouse models. Compared with the respective values in the Sc group, the number of metastatic nodules in mice was found to decrease and survival was prolonged in the shENO2 group. More importantly, WT ENO2, but not the K394-mutant, was found to significantly promote in vivo liver metastases and shorten survival in mice (Fig. 3g, h and Supplementary Fig. S2e).

To characterize the potential clinical relevance of ENO2 K394 acetylation, ENO2 K394 acetylation levels were examined in PDAC samples. Immunoblotting of the PDAC samples showed that ENO2 K394 acetylation levels were significantly lower in the PDAC tissues than in their matched normal tissues (Fig. 3i). Furthermore, in comparison to those in nonmetastatic PDAC tissues, ENO2 K394 acetylation levels were significantly lower in PDAC tissues with liver metastasis (Fig. 3j). Next, we analyzed ENO2 K394 acetylation in a panel of PDAC cell lines and human pancreatic duct epithelial (HPDE) cells. ENO2 K394 acetylation levels were significantly decreased in six established PDAC cell lines relative to those in the nontransformed pancreatic cell line HPDE. In addition, ENO2 K394 acetylation levels in L3.6pl cells with high potential for liver metastasis were much lower than those found in the other low metastatic PDAC cell lines (Supplementary Fig. S2f). Therefore, ENO2 K394 deacetylation plays important roles in promoting PDAC growth and metastasis.

PCAF is a potential acetyltransferase of ENO2. The established role of acetyltransferases and deacetylases in tumor biology led us to search for potential acetyltransferases and deacetylases responsible for ENO2 K394 acetylation. When cotransfected with ENO2, we found that P300/CPBP-associated factor (PCAF), but not GCN5, Tip60, hMOF, CBP or P300, was associated with ENO2 and increased ENO2 K394 acetylation levels (Fig. 4a, left). The interaction of PCAF with endogenous ENO2 was further validated by IP in PDAC cells (Fig. 4a, right). Ectopically expressed PCAF promoted WT ENO2 acetylation but had almost no effect on acetylation of the K394-mutant (Fig. 4b). Furthermore, depletion of endogenous PCAF effectively decreased ENO2 K394 acetylation in PDAC cells, supporting a functional role of PCAF in ENO2 acetylation (Fig. 4c and Supplementary Fig. S3a, b). More importantly, depletion of endogenous PCAF effectively reduced the enzyme activity of ENO2 and suppressed invasion of PDAC cells, which could be rescued by upregulation of PCAF (Fig. 4d, e and Supplementary Fig. S3c). Collectively, these results indicate that PCAF is a potential acetyltransferase of ENO2.

HDAC3 deacetylates and activates ENO2. As TSA was observed to be more potent than NAM for enhancing ENO2 acetylation (Fig. 2a), we then sought to identify which HDAC enzyme(s) mediates ENO2 deacetylation. To test this hypothesis, we first carried out co-IP experiments with ENO2 and several HDAC members and found that ENO2 interacted with HDAC3 but not the other six HDACs when ENO2 and each HDAC were coexpressed in HEK293T cells (Fig. 4f, left). The endogenous protein interaction between HDAC3 and ENO2 could be detected in PDAC cells (Fig. 4f, right). Interestingly, co-overexpression of HA-HDAC3 with Flag-ENO2 WT decreased the acetylation level of ENO2 and increased its enzyme activity. In contrast, co-overexpression of HA-HDAC3 with the K394R/Q mutants did not change the acetylation or enzyme activity of ENO2 (Fig. 4g). However, knockdown of HDAC3 increased the K394 acetylation level (Fig. 4h and Supplementary Fig. S3d, e). Furthermore, knockdown of HDAC3 effectively inhibited ECAR, lactate production and the invasion capacity of PDAC cells, which could be restored by upregulation of HDAC3 (Fig. 4i–k and Supplementary S3f). In addition, we detected the expression level of HDAC3 in human PDAC tissues and found that there was a strong correlation between HDAC3 levels and both ENO2 protein levels and ENO2 K394 acetylation levels (Supplementary Fig. S4a–c). In summary, HDAC3 is the major deacetylase of ENO2 and is responsible for the deacetylation of K394 in PDAC.

The IGF-1/mTOR pathway regulates K394 deacetylation by S424 phosphorylation of HDAC3. Previous studies have shown that the receptor tyrosine kinase (RTK) family plays critical roles in tumor progression and metabolism. Therefore, we hypothesized that some protein factors related to RTK may also act as regulators of ENO2 acetylation. When IGF-1, but not the other factors tested, was added to ENO2-overexpressing PDAC cell lines, ENO2 K394 acetylation was inhibited (Fig. 5a). Furthermore, IGF-1 treatment dose- and time-dependently decreased ENO2 K394 acetylation (Fig. 5b), suggesting that K394 is an important site for the ENO2 deacetylation induced by IGF-1. Then, we sought to investigate how IGF-1 regulates ENO2 K394 acetylation. The suppressive effect of IGF-1 on endogenous ENO2 K394 acetylation could be eliminated when HDAC3 was depleted (Fig. 5c).
Recent studies have identified HDAC3 as a protein that undergoes phosphorylation, with serine (S) 424 representing a key phosphorylation site.\(^{20,21}\) We found that IGF-1 treatment did not change HDAC3 expression but was able to enhance the endogenous S424 phosphorylation of HDAC3 in a time- and dose-dependent manner (Fig. 5b). Furthermore, co-overexpression of ENO2 and WT HDAC3 or the HDAC3 S424D mutant (which mimics phosphorylation\(^{22}\)) could facilitate the deacetylation of WT ENO2 K394. However, the HA-HDAC3 S424A-mutant (which mimics dephosphorylation\(^{23}\)) increased the K394 acetylation level of ENO2. In contrast, co-overexpression of HA-HDAC3 S424A or the S424D mutant with the ENO2 K394Q mutant did not change the acetylation of ENO2 (Supplementary Fig. S5a). In addition, IGF-1 treatment promoted the phosphorylation of HDAC3 S424 and its mediated ENO2 deacetylation when WT HDAC3 was ectopically expressed but had almost no effect on acetylation of K394 when S424A-mutant HDAC3 was ectopically expressed (Supplementary Fig. S5b). However, IGF-1 stimulation did not change the interaction of HDACs with ENO2 (Supplementary Fig. S5c). Furthermore, we checked HDAC3 phosphorylated S424 levels in...
Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3...Zheng et al.

PDAC samples and found that HDACps424 was positively correlated with ENO2 protein expression and negatively correlated with ENO2 K394 acetylation (Supplementary Fig. S4a–c). Collectively, these data suggest that IGF-1 regulates ENO2 K394 acetylation by controlling HDAC3 S424 phosphorylation.

Recent studies have suggested a critical role of the mTOR signaling pathway in PDAC3 phosphorylation.11 In addition, the PI3K/AKT/mTOR pathway is an important pathway regulated by a variety of cellular signals, including IGF-1/IGF-1R.24,25 Therefore, we proposed that the PI3K/AKT/mTOR signaling pathway may regulate ENO2 K394 acetylation in response to IGF-1. To test this hypothesis, we then studied the potential role of the PI3K/AKT/mTOR pathway in IGF-1-mediated signaling regulating ENO2 K394 acetylation. Notably, IGF-1 activated the PI3K/AKT/mTOR pathway in a time- and dose-dependent manner (Fig. 5d). Moreover, both LY294002 (PI3K inhibitor) and rapamycin (mTOR inhibitor) suppressed IGF-1-induced HDAC3 phosphorylation and ENO2 deacetylation at K394 (Supplementary Fig. S6).

Inhibition of IGF-1 increases K394 acetylation and suppresses ENO2 activity. To validate the function of the IGF-1/mTOR pathway in the regulation of ENO2 K394 acetylation, we treated PDAC cells with linsitinib, an oral small-molecule inhibitor of IGF-1R.26,27 Linsitinib dose dependently increased K394 acetylation (Fig. 5e and Supplementary Fig. S7a–c). In addition, inhibition of IGF-1R by linsitinib or shIGF-1-R rescued the inhibition of ENO2 K394 acetylation induced by IGF-1 treatment. However, K394Q mutants showed no change in acetylation levels when the cells were treated with IGF-1 or inhibited by IGF-1R (Fig. 5f and Supplementary Fig. S7d, e). Furthermore, linsitinib or shIGF-1-R effectively ablated the activation of the PI3K/AKT/mTOR pathway and HDAC3 S424 phosphorylation (Fig. 5g and Supplementary Fig. S7f). Treatment with linsitinib or shIGF-1-R significantly decreased the ENO2 activity, colony formation and invasive ability of PDAC cells in vitro, which were increased by IGF-1 (Fig. 5h, i and Supplementary Fig. S7g–i). Collectively, these data indicate that the IGF-1/mTOR pathway is linked to K394 deacetylation and ENO2 activation.

PDAC with ENO2 K394 deacetylation is sensitive to linsitinib. To confirm whether the IGF-1/mTOR pathway regulates K394 deacetylation and the activity of ENO2, we tested the effects of IGF-1R inhibition on the growth and metastasis of PDAC cells driven by overexpression of WT or K394-mutant ENO2 in vivo. Colo357 cells with ENO2 knockdown stably overexpressing WT or K394-mutant ENO2 were used to establish a subcutaneous implantation mouse model and metastatic mouse model, respectively. In subcutaneous xenograft model, treatment of mice with linsitinib was found to decrease the growth rates and sizes of tumors originating from Colo357 cells overexpressing WT ENO2 but had no effect on the growth rates and sizes of tumors derived from cells expressing K394-mutant ENO2 (Fig. 6a–c). Addition, in the metastatic mouse model, linsitinib treatment dramatically decreased liver metastasis of tumors originating from Colo357 cells overexpressing WT ENO2 but not that of tumors originating from cells overexpressing K394-mutant ENO2 (Fig. 6d–f). Furthermore, treatment of mice with linsitinib significantly decreased the activation of the PI3K/AKT/mTOR pathway and HDAC3 S424 phosphorylation (Supplementary Fig. S8c).

As epithelial-mesenchymal transition (EMT) is suggested to be closely associated with cancer metastasis,28 we wondered whether EMT is the molecular mechanism by which IGF promotes PDAC metastasis by enhancing ENO2 activity. As expected, knockdown of ENO2 induced an increase in E-cadherin levels and significant decreases in the expression levels of N-cadherin, vimentin, Snail1 and Twist1 in both PDAC cells (Supplementary Fig. S9a) and subcutaneous xenograft models (Supplementary Fig. S9b). In addition, to identify whether IGF-1 is involved in the ENO2-induced enhancement of EMT, we assessed EMT markers in E2O2-upregulated PDAC cells treated with IGF-1 or linsitinib. Treatment with IGF-1 increased the EMT phenotype in E2O2-upregulated PDAC cells, with decreased E-cadherin and increased N-cadherin, vimentin, Snail1 and Twist1 levels. In contrast, linsitinib treatment led to a reversal of the pro-EMT effect by ENO2 both in vitro (Supplementary Fig. S9c) and in vivo (Supplementary Fig. S9d).

Together, these findings suggest that linsitinib treatment showed different effects on the growth and metastasis of PDAC cells depending on the cells overexpressed WT or K394-mutant ENO2. K394 acetylation plays a key role in regulating ENO2 function upon linsitinib treatment (Fig. 6h).

**DISCUSSION**

Metabolic reprogramming has been proven to play important roles in cancers.29 In pancreatic cancer, the extreme hypovascular and hypoxic microenvironments severely restrict nutrient...
availability. The adaptation of cellular metabolism by the tumor is particularly important for maximizing energy acquisition. ENO2, also referred to as NSE, is an important enzyme in glycolysis and a well-established tumor biomarker for small-cell lung cancer, prostate cancer, and so on. Studies have found that ENO2 is essential for cancer cell survival, proliferation and progression in glioblastoma multiforme and HCC. However, the function of ENO2 in pancreatic cancer has not been fully clarified. In our study, we first observed that high ENO2 expression was closely correlated with metastasis and poor survival in PDAC patients. Many recent works from our group and others have suggested that metabolic enzymes play important roles in EMT. Our current study reinforces the notion that metabolic enzymes such as ENO2 are an important promoter of PDAC metastasis, and more importantly, we found that ENO2 promotes PDAC metastasis by, at least in part, inducing EMT in PDAC cells. Given that PDACs are
known to be highly malignant human tumors, it appears that ENO2 may serve as a novel metabolic biomarker for prognosis prediction, as well as a potential therapeutic target to block PDAC metastasis.

Previous studies have indicated that the majority of intermediate metabolic enzymes are acetylated and that the acetylation of metabolic enzymes plays an important role in tumorigenesis and the progression and metastasis of cancer. In our study, we determined that acetylation at K394, a site located in the active center of ENO2, played an important role in regulating ENO2 enzymatic activity and glycolytic metabolism in PDAC. More importantly, from investigations in clinical samples and cell lines, we provided both in vitro and in vivo evidence suggesting a novel function of ENO2 K394 deacetylation in promoting PDAC growth and metastasis. This suggests that ENO2 K394 deacetylation is in line with other regulatory mechanisms identified for ENO2 and may play a dramatic role in PDAC. Furthermore, these findings stress that aberrant deacetylation of ENO2 not only represents a key event contributing to PDAC metastasis but also can be targeted for the treatment of tumors with ENO2 deacetylation.

It is widely accepted that the biological activity of Kac is regulated by both acetyltransferases and deacetylases. We identified that both the acetyltransferase PCAF and the deacetylase HDAC3 play key roles in controlling ENO2 K394 acetylation. HDAC3, a member of the histone deacetylase family, is important in both physiological processes, such as the regulation of major metabolic and energy utilization pathways, and the development of different cancers. Previous studies have described the phosphorylation of S424 as critical for HDAC3 activity. Supporting this notion, we showed in this study that another metabolic enzyme, ENO2, is a direct substrate of HDAC3 and that the ENO2 deacetylation mediated by S424 phosphorylation of protein HDAC3 plays an important role in regulating ENO2 activity/function to drive PDAC progression, possibly via EMT.

IGF-1 exerts its effect through autocrine, paracrine, and endocrine mechanisms. IGF-1 plays an important role in tumorigenesis, angiogenesis, proliferation, and metastasis in various cancers. Studies have proven that the IGF-1/mTOR signaling pathway can facilitate cancer cell survival. The PI3K/AKT/mTOR pathway satisfies the metabolic demands for cancer proliferation, invasion and metastasis by allowing the utilization of amino acid substrates and one-carbon units. We demonstrate that the PI3K/AKT/mTOR pathway regulates ENO2 K394 deacetylation upon IGF-1 stimulation. Given the poor prognosis of PDAC, novel means of intervention are urgently needed. Several potent and selective IGF-1R inhibitors or antagonists are now in different stages of clinical development, including phase I/randomized phase II (dalotuzumab) and phase Ib/II (ganimubat) trials in multiple solid tumors. Linsitinib, also named OSI-906, is an orally bioavailable selective small-molecule tyrosine kinase inhibitor of both human IGF-1R and insulin receptor (IR). Linsitinib has been proven to have antiproliferative effects in cell lines and xenograft models in a variety of cancers.

In our study, we observed that linsitinib treatment blocked the IGF-1-induced deacetylation of ENO2 and suppressed EMT, thereby inhibiting tumor growth and liver metastasis, indicating the potential clinical value of linsitinib in preventing liver metastasis in patients with deacetylated ENO2.

Conclusions

Our study indicated that deacetylation of ENO2 K394 promotes metastasis of PDAC. Both the acetyltransferase PCAF and the deacetylase HDAC3 play key roles in regulating ENO2 K394 acetylation. The IGF-1/PI3K/AKT/mTOR pathway induces K394 deacetylation to stimulate ENO2 activity by increasing the phosphorylation of HDAC3 at S424, thereby promoting liver metastasis in PDAC. IGF-1R inhibitors such as linsitinib might be exploited for therapeutic benefit as effective adjuvant anticancer treatments for PDAC patients with deacetylated ENO2. Here, we propose an interesting possibility to develop a potential therapeutic strategy to block ENO2 function and control PDAC metastasis.

Materials and Methods

Datasets, samples and follow-up

Data from GSE28735 and GSE15471 were retrieved from the public GEO database (http://www.ncbi.nlm.nih.gov/geo). The mRNA expression of target genes was calculated as fragments per kilobase of transcript per million fragments mapped values compared with β-actin. A total of 284 PDAC patients were enrolled in this study. Paired tumor and adjacent nontumor pancreas...
tissues were collected from patients who had undergone surgical resection for PDAC at the author's institute with signed informed consent forms. The tissue specimens were immediately frozen in liquid nitrogen or fixed in 10% formalin and paraffin embedded. None of these patients had received any antitumor treatment preoperatively. The study was approved by the Ethics Committee of Fudan University (2018-164). In all 284 patients, 271 cases were collected between January 2012 and December 2014 for TMA construction. The clinicopathological profiles of the TMA cohort patients are summarized in Supplementary Table S1. The follow-up was completed in December 2017 with a median follow-up of 11 months (range 1–63 months). During the follow-up period, patients were re-evaluated by routine blood tests, computed tomography or magnetic resonance imaging every 3 months. An additional five paired tissues and eight pancreatic cancer tissues with no metastasis (from MFPs) or liver metastasis (from LMPs) from patients were collected to detect ENO2 and ENO2 K394 acetylation levels.
Western blot was performed as described in a previous study. Protocol, followed by denaturation with SDS loading buffer. (Merck & Co Inc., NJ, USA) according to the manufacturer buffer, and the protein was eluted by using Flag peptides at 4 °C. The beads were then washed three times with ice-cold NP-40 buffer containing 0.01 mol/L sodium citrate (pH 6.0) in a microwave oven for 10 min after deparaffination and rehydration. The sections were then incubated with anti-ENO2 antibodies as described above at 4 °C overnight and subsequently developed using the ChemMate Dako EnVision Detection Kit, Peroxidase/DAβ, Rabbit/Mouse (DakoCytomation, Glostrup, Denmark). The slides were then counterstained with hematoxylin. For negative controls, all procedures were conducted with the primary antibody omitted. Image-Pro Plus v6.0 software (Media Cybernetics Inc., MD, USA) was used to assess the immunostaining by mean optical density, as previously described. The cutoff of ENO2 was defined as the mean of all values.

IP and western blot
The indicated cells were lysed in ice-cold NP-40 buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% NP-40 and protease inhibitor cocktail (Roche, Basel, Switzerland) with rotation at 4 °C for 1 h. Lysates were centrifuged at 12,000 x g for 15 min at 4 °C. The supernatant was incubated with M2 anti-Flag mAb agarose beads (Merck & Co Inc., NJ, USA) for 3–5 h at 4 °C or incubated with the indicated antibody for 1 h, followed by incubation with Protein A beads (Solastra Cruz Biotechnology, Inc., CA, USA) for another 3 h at 4 °C. The beads were then washed three times with ice-cold NP-40 buffer, and the protein was eluted by using Flag peptides (Merck & Co Inc., NJ, USA) according to the manufacturer’s protocol, followed by denaturation with SDS loading buffer. Western blot was performed as described in a previous study. For the acetylation western blot, buffer containing 50 mM Tris (pH 7.5) with 10% (v/v) Tween-20 and 1% peptone (Amresco, WA, USA) was used for blocking, and 5% BSA was used to prepare primary and secondary antibodies.

Frozen human PDAC tissues were ground and lysed in ice-cold 0.5% NP-40 buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and protease and phosphatase inhibitor cocktail, with rotation at 4 °C for 1.5 h. IP was performed with the anti-ENO2 antibody, followed by western blot with the antibodies indicated. Immunoblotting intensity was quantified by using Image Quant TL software (GE Healthcare, USA).

Antibody and chemicals
Antibodies against the following molecules were used in this study: ENO2 (#8171), pan-acetylated lysine (#9441), Flag (#14793), β-actin (#4970), HDAC3 (#85057), HA (#3724), Myc (#2276), PCAF (#3305), phospho-HDAC3-S424 (#3815), p-IGF-1R/IR (#3021), IGF-1R (#9750), IR (#3025), phospho-p70 S6K (Thr389) (#2394), AKT (#4691), pAkt-Ser473 (#4060), pAkt-Thr308 (#13038), ERK (#4695), pErk1/2 (Thr202/Tyr204) (#9101), vimentin (#5741), N-cadherin (#13116), Snail (#3879), E-cadherin (#3195), Twist1 (#46702) and ENO1 (#3810), which were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-ENO2 antibody (ab79757) was purchased from Abcam. A site-specific antibody to detect ENO2 K394 acetylation (anti-AcK394, 1:1000) was generated by synthesizing the peptide CTGQIK (Ac) TGAPCRS to detect ENO2 K394 acetylation (anti-AcK394, 1:1000) was generated by synthesizing the peptide CTGQIK (Ac) TGAPCRS (Huiou Biotech Ltd., Shanghai, China), followed by coupling to KLH as an antigen to immunize rabbits. Antiserum was collected after four doses of immunization, followed by antibody purification.

Nicotinamide was purchased from Sigma-Aldrich. Trichostatin A, LY294002, rapamycin and linsitinib were purchased from Selleck Chemicals (Houston, TX, USA). Insulin, IGF-1, epidermal growth factor (EGF), transforming growth factor β (TGFβ), colony-stimulating factor (CSF1) and hepatocyte growth factor (HGF) were purchased from PeproTech (Rocky Hill, NJ, USA). Insulin (100 ng/mL, 12 h), IGF-1 (100 ng/mL, 12 h), EGF (30 ng/mL, 24 h), TGFβ (10 ng/mL, 72 h), CSF1 (10 ng/mL, 30 min) and HGF (50 ng/mL, 30 min) were used to treat PDAC cells for the indicated times. Biotinylated peptides of ENO2 containing either an acetylated or a nonacetylated K394 residue were purchased from Huiou Biotech Ltd (Shanghai, China).

Enzyme activity
Flag-tagged ENO2 protein was overexpressed in HEK293T or Colo357 cells as indicated, followed by IP. The immunoprecipitate was eluted by adding 150 mg/mL Flag peptides dissolved in 1 mL PBS (pH 7.5). ENO2 activity was measured using a flow fluorometric NADH-linked assay as previously described. The reactions were started by adding enzyme into the buffer containing 100 mM triethanolamine at pH 7.4, 56 mM DPG, 400 μM NADH, 5 mM MgSO4, 10 mM KCl, 2 mM ADP, and PK/LDH enzyme solution (Merck & Co Inc., NJ, USA). Enolase converts 2-PGA to PEP, the substrate of pyruvate kinase. Pyruvate formed by this reaction is linked to NADH oxidation by LDH. Enolase activity was determined by fluorescence measurement of NADH oxidation (Ex340 nm, Em460 nm) using a Hitachi F-4600 fluorescence spectrophotometer.

ECAR and lactate assay
The ECAR assay was performed using a Seahorse Bioscience XFe 96 analyzer (Seahorse Bioscience, MA, USA) according to the manufacturer’s instructions. PDAC cells were counted and seeded into a Seahorse 96-well plate at a density of 1–2 ×10^4 cells/well, followed by culture for 12 h. After that, 10 mM glucose, 2 μM oligomycin and 2-deoxy-D-glucose were added into different ports of the Seahorse cartridge. Each data point was the average of five independent measurements.

Lactate production of PDAC cells was quantified using the BioVision Lactate Assay Kit (Bio Vision, CA, USA). Then, 0.5 μL culture medium collected from the treated cells as indicated was added to lactate assay buffer. The reaction was incubated for...
30 min at room temperature, and absorbance was measured at 570 nm using a microplate reader.

Animal studies
All animal experiments were approved by the Animal Ethics Committee of Fudan University (2018020885). Colo357 cells with ENO2 knockdown and Colo357 cells with ENO2 knockdown plus reintroduced with WT ENO2 or K394Q mutants were injected subcutaneously into the flanks of 4-week-old male nude mice (5 × 10^6 cells/mouse, n = 5–6 for each group). For treatment, when the tumor volume reached ~100 mm^3, the mice were administered either 50 mg/kg linsitinib or vehicle orally once daily, on a 5 days on and 3 days off cycle, by oral gavage. Tumor volumes were measured every 4 days, and mice were sacrificed 28–32 days after injection. Xenograft tumors were collected and photographed, and tumor volume and weight were measured. In the metastatic NOD/SCID mouse model, Colo357 cells (2.5 × 10^6 cells per mouse, n = 6) were implanted into the subcapsular region of the spleen of five mice (5-week-old male NOD/SCID mice) as described previously. For treatment, mice were treated orally with either 50 mg/kg linsitinib or vehicle, once daily, on a 5 days on and 3 days off cycle, by oral gavage 1 week after implantation and sacrificed 28 days later. The liver was harvested, and H&E staining was performed for metastatic nodule analysis.

Statistical analysis
Quantitative data were expressed as the mean ± standard deviation (SD), while qualitative data were shown as the number (percent) or median (range) when appropriate. If the data were normally distributed and the variation between groups was minimal, paired Student’s t test was used to compare mean values between paired samples of two independent groups, and unpaired Student’s t test was applied for mean value comparison between two independent groups. If the variation among three or more groups was minimal, ANOVA followed by Bonferroni test was applied for comparison of multiple groups. For treatment, mice were treated orally with either 50 mg/kg linsitinib or vehicle, once daily, on a 5 days on and 3 days off cycle, by oral gavage 1 week after implantation and sacrificed 28 days later. The liver was harvested, and H&E staining was performed for metastatic nodule analysis.

ACKNOWLEDGEMENTS
The authors thank Professor Christiane Bruns, Kuizhi Wang, Hongquan Zhang, Kunliang Guan and Yue Xiong for providing pancreatic cancer cell lines and plasmids. The authors thank Doctor Xiaoxiang Zhu for kindly helping with the statistical analysis of the paper. This work was supported by the National Key Research and Development Program of China (No. 2017YFC1308604), the Shanghai Program for Innovative Research Team in Universities, the National Natural Science Foundation of China (No. 81802903, 81722000, 81722532, 81930074 and 81873256), the NSFC Program of International Cooperation and Exchanges (No. 81210180816), the National Key Basic Research Program of China (No. 2013CB910500 and 2014CB542101), and China National Key Projects for Infectious Disease (No. 2012ZX10002-012).

AUTHOR CONTRIBUTIONS
Y.Z., C.W. and J.Y. contributed equally to this work and performed the experiments, analyzed data, and wrote the manuscript; F.Y., H.J. and D.F. provided patient tissue samples and collected patient clinical information; M.X., D.X., C.W., B.H., Z.Z., T.L., S.Y. and K.W. performed the experiments and analyzed the data; Y.Z., P.N. and C.B. revised the manuscript; L.Q. and Q.D. designed and supervised the entire project, designed the experiments, and wrote the manuscript. All authors have participated actively in this work and approved the final manuscript.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41392-020-0146-6) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

Ethics approval and consent to participate: All clinical samples were collected with informed consent from patients, and the study was approved by the Ethics Committee of Fudan University. In vivo experiments were carried out in accordance with and under approval of the Animal Ethics Committee of Fudan University.

REFERENCES
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018).
2. Allemani, C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018).
3. Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039–1049 (2014).
4. Makohon-Moore, A. & Iacobuzio-Donahue, C. A. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer 16, 553–565 (2016).
5. Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657–669 (2017).
6. Budhu, A. et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144, 1066–1075 e1061 (2013).
7. Feig, C. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266–4276 (2012).
8. Perera, R. M. & Bardeesy, N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 5, 1247–1261 (2015).
9. Edderkaoui, M. et al. An inhibitor of GSK3β and HDACs kills pancreatic cancer cells and slows pancreatic tumor growth and metastasis in mice. Gastroenterology 155, 1985–1996, e1985 (2018).
10. Senbabaoglu, Y. et al. A multi-method approach for proteomic network inference in 11 human cancers. PLoS Comput. Biol. 12, e1004765 (2016).
11. Hu, H. et al. Acetylation of PKR1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology 65, 515–528 (2017).
12. Li, F. et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat. Commun. 9, 508 (2018).
13. Guan, K. L. & Xiong, Y. Regulation of intermediary metabolism by protein acetylation. Trends Biochem. Sci. 36, 108–116 (2011).
14. Shakespear, M. R. et al. Lysine deacetylases and regulated glycolysis in macrophages. Trends Immunol. 39, 473–486 (2018).
15. Carney, D. N. et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1, 583–585 (1982).
16. Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70, 10202–10212 (2010).
17. Hombreck, P. V. et al. 15 years of PhosphoSitePlus(R): integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 47, D433–D441 (2019).
18. Zhao, S. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010).
19. Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).
20. Zhang, X. et al. Histone deacetyase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev. 19, 827–839 (2005).
21. McGee-Lawrence, M. E. et al. Hdac3 deficiency increases marrow adiposity and induces lipid storage and glucocorticoid metabolism in osteochondrogenic cells. J. Bone Miner. Res. 31, 116–128 (2016).
22. Guo, H. & Friedman, A. D. Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J. Biol. Chem. 286, 208–215 (2011).
23. Wang, S. et al. Insulin and mTOR pathway regulate HDAC3-mediated deacetylation and activation of PKG1. PLoS Biol. 13, e1002243 (2015).
24. Kaypee, S. et al. Aberrant lysine acetylation in tumorigenesis: implications in the development of therapeutics. Pharmacol. Ther. 162, 98–119 (2016).
25. Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
26. Tommelein, J. et al. Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF-1R activation. Cancer Res. 78, 659–670 (2018).
27. Amaral, A. T. et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clin. Cancer Res. 21, 1373–1382 (2015).

28. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).

29. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337–342 (2012).

30. Lu, M. et al. ACOT12-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition. Cell Metab. 29, 886–900, e885 (2019).

31. Zhang, Z. et al. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. Br. J. Cancer 122, 209–220 (2020).

32. Wu, X. et al. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. J. Exp. Med. 214, 1065–1079 (2017).

33. Sun, Z. et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18, 934–942 (2012).

34. Zhang, L. et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis. J. Clin. Invest. 127, 2159–2175 (2017).

35. Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16, 3–34 (1995).

36. Png, K. J., Halberg, N., Yoshida, M. & Tavazoie, S. F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481, 190–194 (2011).

37. Wu, Y. et al. Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res. 70, 57–67 (2010).

38. Vaira, V. et al. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26, 2678–2684 (2007).

39. Abdel-Wahab, R. et al. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J. Hematol. Oncol. 11, 71 (2018).

40. McCaffrey, I. et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF-1R inhibitor. Clin. Cancer Res. 19, 4282–4289 (2013).

41. Mulvihill, M. J. et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153–1171 (2009).

42. McKinley, E. T. et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res. 17, 3332–3340 (2011).

43. Chen, W. et al. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 77, 5107–5117 (2017).

44. Zhu, X. D. et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 26, 2707–2716 (2008).

45. Wang, Y. P. et al. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. Embo. J. 33, 1304–1320 (2014).

46. Cui, L. et al. Small nucleolar noncoding RNA SNORA23, up-regulated in human pancreatic ductal adenocarcinoma, regulates expression of spectrin repeat-containing nuclear envelope 2 to promote growth and metastasis of xenograft tumors in mice. Gastroenterology. 153, 292–306, e292 (2017).